Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
Colleen Loo, Nick Glozier, David Barton, Bernhard T Baune, Natalie T Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, · 2023
Read Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial by Colleen Loo, Nick Glozier, David Barton, Bernhard T Baune, Natalie T Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10727911.txt.
Description
Colleen Loo and co-authors report a phase 3 trial of ketamine injections for depression that has not responded to standard treatment. The trial ran at seven centres in Australia and New Zealand, and patients got twice-weekly injections under the skin of either ketamine or midazolam for four weeks. One group got a fixed dose. A second group got flexible doses that rose when response was weak.
In the flexible-dose group, ketamine clearly beat the comparison drug: about one in five patients reached remission, against one in fifty on midazolam. In the fixed-dose group the two drugs did not differ. Side effects such as odd mental states and raised blood pressure settled within two hours, and the drug was well tolerated. The authors conclude that well-dosed under-skin ketamine is a practical, effective option for hard-to-treat depression over a four-week course.
Catalog record
| CREATOR | Colleen Loo, Nick Glozier, David Barton, Bernhard T Baune, Natalie T Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |